Market revenue in 2023 | USD 65.9 million |
Market revenue in 2030 | USD 116.5 million |
Growth rate | 8.5% (CAGR from 2023 to 2030) |
Largest segment | Human donor tissue-derived products |
Fastest growing segment | Human Donor Tissue-Derived Products |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Human Donor Tissue-Derived Products, Acellular Animal-derived Products |
Key market players worldwide | 3M Co, Organogenesis Holdings Inc Class A, Integra Lifesciences Holdings Corp, Smith & Nephew PLC, MiMedx Group Inc, Essity AB Class B, Stryker Corp, Vericel Corp, Mallinckrodt PLC Ordinary Shares - New, Tissue Regenix |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biological skin substitutes market will help companies and investors design strategic landscapes.
Human donor tissue-derived products was the largest segment with a revenue share of 67.07% in 2023. Horizon Databook has segmented the Europe biological skin substitutes market based on human donor tissue-derived products, acellular animal-derived products covering the revenue growth of each sub-segment from 2018 to 2030.
Europe is one of the most advanced regions globally with advanced technologies and infrastructure, resulting in better healthcare facilities and patient care. Players seeking entry into the Europe market require extensive knowledge regarding different regulatory procedures and services in various member states of the European Union.
Small and midsized medical device companies without a regulatory affairs department usually hire a regulatory consultant or a legal representative to assist them through the various stages of the regulatory approval processes required for commercializing their products in Europe. Medical device manufacturers in the EU are anticipated to face major changes in the old regulatory framework, which would affect market access or entry.
The EU Medical Device Regulations (MDR) are expected to replace the current Medical Device Directive (93/42/EEC) and the Directive on active implantable medical devices (90/385/EEC).
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe biological skin substitutes market , including forecasts for subscribers. This continent databook contains high-level insights into Europe biological skin substitutes market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account